This phase II trial is to evaluate the safety and effectiveness of using a novel immunotherapy (M7824) in conjunction with and following concomitant chemoradiation therapy (cCRT) in patients with inoperable, advanced non-small cell lung cancer..
This trial is treating patients with inoperable, Stage III non-small cell lung cancer.
This is a systemic therapy.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
All patients eligible to participate in this trial will receive cCRT, which involves intravenous administration of Cisplatin/Etoposide or Carboplatin/Paclitaxel or Cisplatin/Pemetrexed along with radiation therapy. In addition patients will either receive M7824 during and after cCRT, or a placebo during and another immunotherapy (Durvalumab) after the cCRT.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More